Evidence map›Paper›PMID 16923951›Full record

ArticleAntimicrobial agents and chemotherapy2006

Candida albicans biofilms produce antifungal-tolerant persister cells.

Michael D LaFleur, Carol A Kumamoto, Kim Lewis

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers.

0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

211 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Quiescence improvesbioRxiv : the preprint server for biology · 2026
    Article
  7. Comprehensive Insights into Sugar Transporters ofJournal of fungi (Basel, Switzerland) · 2026
    Article
  8. [Chlorhexidine and Polident Induce the Formation ofSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  9. Article
  10. Review
  11. The pathogenicity and future treatment strategies ofFrontiers in cellular and infection microbiology · 2026
    Review
  12. OvercomingFrontiers in antibiotics · 2026
    Review
  13. Review
  14. Article
  15. StudyingPharmaceuticals (Basel, Switzerland) · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

151 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael D LaFleurDepartment of Biology, Northeastern University, 360 Huntington Ave., 134 Mugar Hall, Boston, MA 02115, USA.
Carol A Kumamoto
Kim Lewis

Funding

A GENOMICS APPROACH TO P. AERUGINOSA BIOFILMSR01GM061162 · NIGMS · TUFTS UNIVERSITY MEDFORD · PI LEWIS, KIM · 2000 to 2011
$4.2M
Regulation of Drug Resistance Genes in C. AlbicansR01AI052805 · NIAID · TUFTS UNIVERSITY BOSTON · PI KUMAMOTO, CAROL A. · 2003 to 2007
$1.4M
NIAID NIH HHS AI052805NIAID NIH HHS R01 AI052805NIGMS NIH HHS 2 R01 GM061162-05A1NIGMS NIH HHS R01 GM061162
6 · The paper itself

Abstract

Fungal pathogens form biofilms that are highly recalcitrant to antimicrobial therapy. The expression of multidrug resistance pumps in young biofilms has been linked to increased resistance to azoles, but this mechanism does not seem to underlie the resistance of mature biofilms that is a model of in vivo infection. The mechanism of drug resistance of mature biofilms remains largely unknown. We report that biofilms formed by the major human pathogen Candida albicans exhibited a strikingly biphasic killing pattern in response to two microbicidal agents, amphotericin B, a polyene antifungal, and chlorhexidine, an antiseptic, indicating that a subpopulation of highly tolerant cells, termed persisters, existed. The extent of killing with a combination of amphotericin B and chlorhexidine was similar to that observed with individually added antimicrobials. Thus, surviving persisters form a multidrug-tolerant subpopulation. Interestingly, surviving C. albicans persisters were detected only in biofilms and not in exponentially growing or stationary-phase planktonic populations. Reinoculation of cells that survived killing of the biofilm by amphotericin B produced a new biofilm with a new subpopulation of persisters. This suggests that C. albicans persisters are not mutants but phenotypic variants of the wild type. Using a stain for dead cells, rare dark cells were visible in a biofilm after amphotericin B treatment, and a bright and a dim population were physically sorted from this biofilm. Only the dim cells produced colonies, showing that this method allows the isolation of yeast persisters. Given that persisters formed only in biofilms, mutants defective in biofilm formation were examined for tolerance of amphotericin B. All of the known mutants affected in biofilm formation were able to produce normal levels of persisters. This finding indicates that attachment rather than formation of a complex biofilm architecture initiates persister formation. Bacteria produce multidrug-tolerant persister cells in both planktonic and biofilm populations, and it appears that yeasts and bacteria have evolved analogous strategies that assign the function of survival to a small part of the population. In bacteria, persisters are dormant cells. It remains to be seen whether attachment initiates dormancy that leads to the formation of fungal persisters. This study suggests that persisters may be largely responsible for the multidrug tolerance of fungal biofilms.

Indexed as

Antifungal AgentsBiofilmsCandida albicansChlorhexidineDisinfectantsDrug Resistance, Multiple, FungalFluoresceinsMicrobial Sensitivity TestsMicroscopy, FluorescencePhenotypeAntifungal AgentsChlorhexidinediacetylfluoresceinDisinfectantsFluoresceins

Identifiers

PMID16923951
PMCPMC1635216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.